Aims: To decrease overall treatment time (OTT) and to compare the clinical outcome of interdigitated high-dose-rate intracavitary brachytherapy (HDRICBT) versus sequential HDRICBT with external beam radiotherapy (EBRT) in the treatment of locally advanced carcinoma cervix.
INTRODUCTION
Cervical cancer is the second most common cancer among women in the world after breast cancer and is the most common cancer among Indian women. [1] [2] [3] [4] The majority of patients in India present with advanced stage of disease, and the NCI recommends platinum-based concurrent chemoradiation as a standard of care for these patients. [5] [6] [7] The curative potential of radiation therapy in the management of carcinoma cervix is greatly enhanced by the use of intracavitary brachytherapy (ICBT). Hence, a combination of external beam megavoltage irradiation along with ICBT is considered mandatory for proper and adequate delivery of radiation dose. The success of brachytherapy is attributed to the fact that there is delivery of a high radiation dose directly to the tumor while sparing the surrounding normal tissues due to a rapid dose falloff. High-dose-rate (HDR) and low-dose-rate brachytherapy appear to be relatively equivalent treatments in terms of survival outcomes based on existing retrospective and prospective studies. [8] [9] [10] [11] [12] [13] [14] [15] [16] Advantages of HDR brachytherapy include opportunities for outpatient treatment, avoidance of exposure to staff from the radiation source, consistent and reproducible applicator positioning, and dose optimization attained with a variable dwell-time stepping source. [16] Nevertheless, with HDR brachytherapy, there is significant variation of the total tumor dose, the dose delivered per fraction, and the proportion of tumor dose delivered with external beam radiotherapy (EBRT) versus brachytherapy. [17] Fractionation and dose adjustments of the total dose are crucial factors in lowering the frequency of complications without compromising the treatment results. While smaller number of fractions or large fraction size (2 or 3) is convenient for patients, they could lead to excessive rectal or bladder toxicity. Nevertheless, in many countries where there is a great incidence of this pathology, the cost of treatment increased proportionally to the number of fractions used individually and the design of an optimal treatment program depends on the requirements of each particular center.
Another issue in incorporating the HDRICBT with EBRT is the time of administration and overall treatment time (OTT). Several studies have described lower pelvic tumor control and survival rates when the OTT in the course of irradiation is prolonged. [18, 19] The American Brachytherapy Society (ABS) recommends that the total treatment duration including EBRT and ICBT should be <8 weeks. Some studies have suggested that there may be as much as 1% decrease in survival and local control for each extra day of treatment beyond a total treatment time of 55-60 days. [18, 19] The OTT would be unduly prolonged if ICBT will begin after completion of EBRT. A number of efforts have been made to improve OTT. In this regard, HDRICBT can be interdigitated during EBRT if vaginal geometry is suitable for brachytherapy application to decrease the OTT. [20, 21] However, in our setup where most of the patients present in advanced stage, cervical os negotiability and attaining suitable geometry for applicators during EBRT are the major challenge and limitation.
This study was designed to address these issues. In this study, we evaluated the feasibility of HDRICBT during EBRT and compared the outcome of interdigitated HDRICBT with the sequential HDRICBT.
METHODS
It was a prospective randomized study conducted from January 2014 to July 2015 in the Department of Radiotherapy, J N Medical College, AMU, Aligarh. A total of 82 histologically confirmed and untreated patients of locally advanced carcinoma cervix having minimum Karnofsky Performance Score of 70 belonging to Stage IIB to IIIB were enrolled. Informed written consent was taken. They were randomized into study group and control group. In the study group, HDRICBT was given in interdigitated form during EBRT. In the control group, HDRICBT was given in the sequential form after the completion of EBRT. Concurrent cisplatin was administered on a weekly basis in both the arms.
The patients in the study group received EBRT 40 Gy/20 fractions followed by 10 Gy/5 fractions with midline shielding to total dose of 50 Gy/25 fractions 5 days a week. After completion of 30 Gy in 15 fractions of EBRT, patients were evaluated for the first fraction of HDRICBT. If os was negotiable and geometry was suitable, then HDRICBT of 8 Gy was delivered to point A. Similarly, second and third fractions of interdigitated HDRICBT were given at weekly interval on consecutive weeks. These interdigitated HDRICBT fractions were delivered on non-EBRT days. Patients were excluded from the study if the geometry was found to be unsuitable even after 40 Gy of EBRT. Patients in the control group received EBRT 40 Gy/20 fractions followed by 10 Gy/5 fractions with midline shielding to total dose of 50 Gy/25 fractions 5 days a week. It was followed by three fractions of sequential HDRICBT as 8 Gy/fraction/week.
Concurrent chemotherapy
Dexamethasone, 5-HT3 antagonists, and pantoprazole were given as antiemetic prophylaxis/premedication. Concurrent chemotherapy consisted of intravenous infusion of cisplatin (40 mg/m 2 ) over 3 h with adequate hydration on a weekly basis usually on day 1 or 2 of the week. Chemotherapy was never given on the day of brachytherapy in the experimental arm. Irradiation will be given on these days about 1-2 h after completion of cisplatin chemotherapy infusion.
EBRT was delivered to the pelvis by anteroposterior/ posteroanterior or four fields box technique by Telecobalt unit. HDRICBT was delivered by remote after loading MicroSelectron Ir-192 HDR unit. The applicator system used was Fletcher Williamson applicators with intrauterine tandem and vaginal colpostats of different sizes of shielded ovoids according to the individual patient geometry. In point A rectal and bladder dose was calculated and monitored using standard International Commission on Radiation Units and Measurements (ICRU) 38 method. Semi-orthogonal X-ray was taken to identify the applicator's prescription points and patient's points such as bladder and rectum.
The brachytherapy dosimetry was based on ICRU 38-point-based recommendations.
During treatment, weekly evaluation was done for acute treatment-related toxicity. The acute reactions were assessed by Radiation Therapy Oncology Group (RTOG), Acute Radiation Morbidity Scoring Criteria. The late reaction was assessed by the RTOG/European Organization for Research and Treatment of Cancer, Late Radiation Morbidity Scoring Schema. Total duration of the treatment included both the external beam and intracavitary components of therapy and was calculated in calendar days starting from the day of the first fraction of EBRT. After the completion of therapy, the patients were evaluated on a monthly basis for the first 3 months. Thereafter, they were followed every 3 months for the whole study period. Response assessment was done 3 months after completion of treatment. Statistical analysis was performed using the two-tailed Chi-square with Yates' correction test and t-test. Statistical significance was considered with P < 0.05.
RESULTS
A total of 82 patients were enrolled 41 in each arm. Treatment was completed as per protocol in 35 patients of the study group and 37 patients of the control group. Six patients in the interdigitated group and four patients in sequential group defaulted during EBRT.
Final analysis was done on 72 patients who have completed the treatment. The maximum incidence of carcinoma cervix was observed between age group of 41-60 years in both the groups. Maximum patients belonged to Stage IIB in both groups: 77.1% in interdigitated group and 75.7% in sequential group [ Table 1 ]. Minimal follow-up was 3 months, whereas maximum follow-up was 18 months.
Response assessment was done 3 months after the completion of treatment. In interdigitated arm, 33/35 (94.3%) patients experienced complete response (CR) and 2/35 (5.7%) had partial response (PR). While in sequential arm, CR was experienced by 34/37 (91.8%) of patients, whereas 3/37 (8.2%) had PR. No patient in both the groups observed stable or progressive disease [ Table 2 ].
Regarding acute toxicities, Grade I and II toxicities were observed in majority of patients in both the groups [ Table 3 ]. Grade III skin toxicity was observed in 11.4% and 8.1% of the study group and control group, respectively. No Grade IV toxicity was noted in both the groups. Grade III vaginal toxicity was observed in 17.1% and 13.5% of the study group and control group, respectively. None of the patients in both the groups had Grade IV vaginal toxicity. Grade III gastrointestinal (GI) toxicity in study group was 2.8%, and there was no Grade IV toxicity in any patient in study group. No Grade III and IV toxicity observed in any patient in control group. No Grade III and IV acute bladder toxicity noted in both the groups. No statistically significant difference regarding acute toxicities was found in both the groups.
Late toxicity was assessed after 3 months of completion of treatment [ Table 4 ]. There was no Grade III and IV late skin toxicity in both the groups. Grade I and II late vaginal toxicity was 94.3% and 94.6% and Grade III toxicity was 5.7% and 5.4% in study group and control group, respectively. No Grade IV late vaginal toxicity was observed in either group. 62.8% and 56.7% patients in study group and control group, respectively, observed Grade I and II late GI toxicity, while Grade III toxicity was observed in 5.7% and 2.7%, respectively. No Grade IV late GI toxicity was found in both the groups. Grade I and II late Total duration of the treatment included both the external beam and intracavitary components of therapy and was calculated in calendar days starting from the day of first fraction of EBRT. Mean OTT in interdigitated group was 40 days ranging from 35 to 53 days while in sequential group was 60 days ranging from 56 to 72 days. Treatment interruption due to treatment-related toxicity was slightly higher in study group than that in control group, but it was statistically insignificant.
Thirty-three patients out of 37 in control arm had satisfactory placement of tandem on day 42 (beginning of brachytherapy). Two patients had a delay of 1-2 weeks. In two patients, applicator placement was not possible at all. Most of the patients were able to complete their entire treatment (89%) within a period of 1-2-week delay from the prescribed week. Out of which, 28 patients (76%) completed the entire treatment within prescribed week (56 days).
Twenty-seven patients out of 35 in the study arm had satisfactory placement of tandem on day 21 (beginning of brachytherapy). Five patients had a delay of 1-2 weeks. In three patients, applicator placement was not possible at all. Most of the patients were able to complete their entire treatment (76%) within a period of 1-2-week delay from the prescribed week. Out of which, 21 patients (60%) completed the entire treatment within prescribed week (35 days).
There was no significant difference regarding applicator placement and delay from prescribed duration of completion of treatment between two arms.
DISCUSSION
In our study, final analysis was done on 72 patients. The median follow-up duration was 10 months. Both the study group and control group were equivalent in terms of acute and late toxicities and response. However, mean OTT was 40 days in interdigitated HDRICBT group while was 60 days in sequential HDRICBT group.
In this study, we have used 8 Gy in three fractions schedule of HDRICBT in both the interdigitated and sequential groups. A variety of dose/fraction schedules of HDRICBT are practiced worldwide. The optimal time dose fractionation schemes are yet to be established. Orton et al. observed wide range of fractionation schedules ranging from 3 to 16.76 Gy per fraction (median 7.46 Gy). [22, 23] Reduction in fraction size would seem to be ideal in light of radiobiological consequences for normal tissue; however, it prolongs the OTT which may directly affect the tumor control rate.
Dose recommendations for HDR brachytherapy by the ABS for locally advanced carcinoma of the cervix depend on the methodology followed for treatment planning. In the United States, the most commonly used regimens are 45 Gy EBRT to the pelvis (possibly with a sidewall boost) with concurrent cisplatin-based chemotherapy and either 5.5 Gy per fraction for five fractions (for patients treated with concurrent chemotherapy who have had either a CR or have 4 cm after EBRT). Over the past decade, the most common HDR fraction size used in the United States for all stages of cervix cancer has been 6 Gy for five fractions, but concerns have been raised about potential toxicity to the sigmoid colon and rectum in patients treated with chemoradiation. [24] Contrary to this, some study shows that even larger dose/fraction is safe and effective. Sood et al. [25] conducted a study using 7-11 Gy per fraction and concluded that two fractions of HDRICBT are safe and effective in the management of cervix cancer, even in conjunction with concomitant cisplatin. The fears that the use of two fractions would lead to excessive rectal or bladder toxicity proved unfounded.
In India too, dose/fraction varies from institution to institution.
Patel et al. [26] concluded that in their setup, HDRICBT at 9 Gy per fraction in two fractions is safe and effective with good local control, survival, and manageable normal tissue toxicity.
Apart from dose/fraction and number of fractions, OTT has a significant impact on treatment outcome. Treatment with EBRT and brachytherapy should be completed in <8 weeks as better local tumor control, and survival can be expected with relatively shorter treatment courses. [27] [28] [29] In a study by Petereit et al., [27] the effect of OTT was analyzed retrospectively. For all stages combined, the 5-year survival (65% and 54%, P = 0.03) and pelvic control rates (87% and 72%, P = 0.006) were significantly different when OTT was more than 55 days. By stage, shorter treatment duration was significant for 5-year overall survival and pelvic control for Stages IB/IIA and III but not for Stage IIB. Authors claimed that survival decreased by 0.6%/day and pelvic control decreased by 0.7%/day for each additional day of treatment beyond 55 days for all stages of disease. In addition, significant late complications were not influenced by treatment time. Similarly, the study conducted by Lanciano et al. [28] demonstrated a highly significant decrease in survival (P = 0.0001) and pelvic control (P = 0.0001) as the OTT was increased from <6, 6-7.9, 8-9.9, and >10 weeks. Stage III accounted for the majority of the adverse effect from the prolongation of OTT. When the analysis was performed by stage to evaluate the effect of OTT with respect to the extent of pelvic disease, it continued to be an independent prognostic factor for infield pelvic control (P = 0.01) and survival (P = 0.02) for Stage III but not Stages I and II.
One of the methods to decrease the OTT is interdigitating the HDRICBT during EBRT. According to the ABS guidelines, HDRICBT may be interdigitated with EBRT to shorten the OTT, with the later typically given in 1.8-Gy fractions to 45 Gy.
However, very few studies are available on timing of HDRICBT insertion during EBRT course. [30] [31] [32] [33] [34] Most of the institution worldwide as well as in our country uses sequential EBRT and ICBT. On analyzing OTT, EBRT requires a minimum of 5 weeks to deliver dose of 45-50 Gy with conventional fractionation schedule and followed by HDR ICBT which requires further many weeks depending upon fraction size and total dose. In case of two fractions of sequential HDRICBT which is a minimum number of fractions mentioned in literature, OTT will be 7 weeks, provided there is no gap between EBRT and HDRICBT. As most commonly used number of fractions in our country is three, the OTT will be 8 weeks. Unfortunately, due to various reasons such as system delay, patient delay, or treatment interruption due to toxicity, it was very unlikely to complete the treatment in stipulated time of 8 weeks which is contrary to the ABS recommendations.
Interdigitated HDRICBT within the course of EBRT appears to be good alternative to sequential HDRICBT to overcome above mentioned possible cause of prolongation of OTT and to keep the treatment time within the recommended time period. In our study, mean OTT in interdigitated group was 40 days ranging from 35 to 53 days while in sequential group was 60 days ranging from 56 to 72 days. It was a significant observation of our study.
In this study, we administered first fraction of HDRICBT after completion of minimum 30 Gy in 15 fractions of EBRT. It was aimed to shrink bulky cervical tumors to enable them to be brought within a higher dose portion of ICBT dose distribution, improve tumor geometry to enable tendon insertion, and sterilize disease in the parametrium and nodal areas that may receive inadequate dose by ICBT. We found that os was negotiable and suitable geometry was achieved in 27 out of 35 patients (77%) at 30 Gy of EBRT (day 21, beginning of interdigitated brachytherapy) in the experimental arm.
Patidar et al. [20] conducted a similar study to evaluate local disease control and early complications of interdigitated HDRICBT with EBRT in early-stage (International Federation of Gynecology and Obstetrics-IB/IIA) carcinoma cervix. They used EBRT 50 Gy/25 fraction in both the groups with interdigitated HDRICBT (5.2 Gy × 5 faraction starting from 1 st week of EBRT) in study group and sequential HDRICBT (7.5 Gy × 3 fraction) in the control group. Median OTT was 38 and 61 days in the study and the control groups, respectively. In our study, OTT was 40 and 60 days, respectively. This difference was obvious as they started HDRICBT from the 1 st week.
In this study, there was no significant difference regarding applicator placement and delay from prescribed duration of completion of treatment between two arms.
In our study, after 3-month follow-up, we observed equivalent response rate in both interdigitated and sequential groups (94.3% and 91.8% CR and 5.7% and 8.1% PR, respectively). Similarly, Patidar et al. found equivalent response rate in both the groups (80% and 60% CR, 16% and 20% PR, respectively).
Although in our study acute toxicities were slightly higher in interdigitated group, they were found to be statistically insignificant. None of the patients in our study developed Grade 4 acute toxicities. Patidar et al. noted similar observations in their study regarding acute toxicities.
Long-term follow-up is needed to comment on late toxicities. The median follow-up duration was 10 months in our study. We observed Grade I and II late toxicities in most of the patients in both the groups. Patidar et al. did not comment over late toxicities.
At our maximum follow-up period, no significant difference in the outcome (response and toxicities) was found in both arms with the advantage of significant reduction in the OTT in experimental arm.
The major achievement of this study was the reduction of OTT using interdigitated HDRICBT. It may result in cost-effective treatment, better patient compliance, and reduced hospital stay. Practical difficulty to achieve suitable geometry during interdigitated HDRICBT was not found to be a significant factor in our study. Small number of patient and short follow-up duration were the major limitations of this study.
CONCLUSION
Interdigitated HDRICBT has equivalent response and toxicities as sequential HDRICBT with the advantage of significant reduction in OTT.
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